SCHEMBL7139042

SCHEMBL7139042

CCCCOC(=O)N1C[C@H](SC(c2ccccc2)(c2ccccc2)c2ccccc2)C[C@H]1C(=O)C#Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 1/20 0.40
BCHE P06276 1/20 0.34
L3MBTL1 Q9Y468 5/20 0.33
MAPK1 P28482 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CHRM2 P08172 4/20 0.32
CHRM4 P08173 4/20 0.32
CHRM5 P08912 4/20 0.32
CHRM1 P11229 4/20 0.32
CHRM3 P20309 4/20 0.32
HPGD P15428 1/20 0.32
ATM Q13315 1/20 0.32
TSHR P16473 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
ACE P12821 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KIF11 P52732 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7165134 0.82 ECE1 (0.38) ECE1BCHEL3MBTL1MAPK1KDM4E
SCHEMBL7139409 0.82 ECE1 (0.38) ECE1BCHEL3MBTL1MAPK1KDM4E
SCHEMBL7151681 0.82 ECE1 (0.52) ECE1BCHEL3MBTL1MAPK1KDM4E
SCHEMBL5415509 0.81 ECE1 (0.41) ECE1BCHEL3MBTL1MAPK1KDM4E
SCHEMBL5492058 0.71 HTRA1 (0.41) ACEKMT2ACYP3A4
SCHEMBL5412731 0.70 PLA2G4A (0.34) ECE1L3MBTL1MAPK1KDM4E
SCHEMBL7811618 0.70 ALDH1A1 (0.42) KDM4ECHRM5CHRM1CHRM3ATM
SCHEMBL5490969 0.69 FABP5 (0.40) ACEKMT2A
SCHEMBL19899348 0.69 ECE1 (0.41) ECE1BCHEL3MBTL1MAPK1KDM4E
SCHEMBL5401096 0.68 NR1H2 (0.42) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ECE1 4/4885BCHE 201/4885L3MBTL1 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.